How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation

被引：11

作者：

Polverelli, Nicola ^{[1
]}

Farina, Mirko ^{[1
]}

D'Adda, Mariella ^{[2
]}

Damiani, Enrico ^{[3
]}

Grazioli, Luigi ^{[4
]}

Leoni, Alessandro ^{[1
]}

Malagola, Michele ^{[1
]}

Bernardi, Simona ^{[1
,5
]}

Russo, Domenico ^{[1
]}

机构：

[1] Univ Brescia, ASST Spedali Civili Brescia, Unit Blood Dis & Bone Marrow Transplantat, Cell Therapies & Hematol Res Program,Dept Clin &, Ple Spedali Civili 1, I-25123 Brescia, BS, Italy

[2] ASST Spedali Civili Brescia, Dept Oncol, Hematol Div, Ple Spedali Civili 1, I-25123 Brescia, BS, Italy

[3] ASST Spedali Civili Brescia, Dept Med & Surg Sci, Div Gen Surg 2, Ple Spedali Civili 1, I-25123 Brescia, BS, Italy

[4] ASST Spedali Civili Brescia, Dept Radiol, Ple Spedali Civili 1, I-25123 Brescia, BS, Italy

[5] ASST Spedali Civili Brescia, CREA Lab, Ctr Ric Ematooncol AIL, Ple Spedali Civili 1, I-25123 Brescia, BS, Italy

来源：

CELLS | 2022年 / 11卷 / 03期

关键词：

myelofibrosis; allogeneic stem cell transplantation; bone marrow transplantation; ruxolitinib; splenectomy; JAK-inhibitors; iron overload; deferasirox; POST-ESSENTIAL THROMBOCYTHEMIA; PROGNOSTIC SCORING SYSTEM; LOW-DOSE THALIDOMIDE; ERYTHROPOIESIS-STIMULATING AGENTS; AGNOGENIC MYELOID METAPLASIA; INTERNATIONAL WORKING GROUP; POLYCYTHEMIA-VERA; MYELOPROLIFERATIVE NEOPLASMS; COMORBIDITY INDEX; PREDICTING SURVIVAL;

D O I：

10.3390/cells11030553

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Moving from indication to transplantation is a critical process in myelofibrosis. Most of guidelines specifically focus on either myelofibrosis disease or transplant procedure, and, currently, no distinct indication for the management of MF candidates to transplant is available. Nevertheless, this period of time is crucial for the transplant outcome because engraftment, non-relapse mortality, and relapse incidence are greatly dependent upon the pre-transplant management. Based on these premises, in this review, we will go through the path of identification of the MF patients suitable for a transplant, by using disease-specific prognostic scores, and the evaluation of eligibility for a transplant, based on performance, comorbidity, and other combined tools. Then, we will focus on the process of donor and conditioning regimens' choice. The pre-transplant management of splenomegaly and constitutional symptoms, cytopenias, iron overload and transplant timing will be comprehensively discussed. The principal aim of this review is, therefore, to give a practical guidance for managing MF patients who are potential candidates for allo-HCT.

引用

页数：20

共 131 条

[1] Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis [J].